Guanglin Luo
About Guanglin Luo
Guanglin Luo is the Scientific Director at BMS, with a background in Chemistry and Organic Chemistry from Fudan University, Brown University, Harvard University, and the Shanghai Institute of Organic Chemistry.
Title
Guanglin Luo is the Scientific Director at BMS.
Education and Expertise
Guanglin Luo's educational background includes a BS in Chemistry from Fudan University, a PhD in Organic Chemistry and Biochemistry from Brown University, an MS in Organic Chemistry from the Shanghai Institute of Organic Chemistry, and postdoctoral training in Organic Chemistry from Harvard University.
Career at BMS
As Scientific Director at BMS, Guanglin Luo has made significant contributions to the field of neurosciences. Luo is the primary inventor for two development candidates: BMS-927711, a CGRP antagonist approved by the FDA as Nurtec ODT at Biohaven Pharma in 2020 for the treatment of migraines, and BMS-986176/LX9211, currently undergoing phase II trials as a novel treatment for neuropathic pain at Lexicon.
Notable Inventions
Guanglin Luo is the primary inventor for BMS-927711, also known as Nurtec ODT, which was approved by the FDA for the treatment of migraines. Additionally, Luo spearheaded the invention of BMS-986176/LX9211, a treatment for neuropathic pain currently in phase II clinical trials.
Conference Presentation
In August 2021, Guanglin Luo presented at the ACS national meeting in Atlanta, GA. The presentation focused on the discovery and development of BMS-986176/LX9211, a highly selective, potent oral and brain penetrable AAK1 inhibitor for neuropathic pain.